Second Sight Medical Products Inc. (NASDAQ:EYES) gains 14% after successful implantation of its Orion I Visual Cortical Prosthesis Print E-mail
By William Kent   
Wednesday, 08 April 2015 14:32

Second Sight Medical Products Inc. (NASDAQ:EYES)’s shares soared 14% after the company has confirmed first successful implant of mechanical model of the Orion or Visual Cortical Prosthesis in the study of an animal.

 

The first implant was done as part of phase I pre-clinical study that is made to evaluate the stability, form as well as biocompatibility.

The study is expected to run till year end and is the first major milestone in the firm’s development of the Orion I. The prototypes that would be fully functional are expected to be finished later in the year with active animal implants planned to start by quarter one of 2016.

The first human clinical trials would start by quarter one of 2017. If initial results are positive in patients, a clinical trial for expansion globally has been planned.

President and CEO of Second Sight, Robert Greenberg, stated that this is a big milestone for the firm but also for those who are affected by all forms of blindness and following the success of Argus II in patients with Retinitis Pigmentosa, the company is looking forward to extending hope of restoring vision to all blind individuals with Orion I.

The Orion I technology depends on FDA-approved Argus II Retinal Prosthesis System. However, it is with updates to electrode neural interface moving from retina to visual cortex.

Orion would bypass retina as well as optic nerve altogether. This gives hope to treat patients with all kinds of blindness where retina is damaged, as in glaucoma, diabetic retinopathy, retinal detachments, trauma, infection, and others.

Population of legally blind people who are potentially eligible for Orion I is 6 million worldwide.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter